Health

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction - News Update

New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.

Shotlee·December 12, 2025·Updated Jan 27, 2026·1 min read

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction

New data reveals that orforglipron, Eli Lilly's oral weight-loss drug candidate, exhibited significant weight reduction in clinical studies, presenting a possible new avenue for those struggling with obesity and associated conditions. The drug is anticipated to be available in 2024.

On Thursday, December 7, 2023, Eli Lilly revealed that its experimental oral drug, orforglipron, resulted in weight loss of up to 29% during clinical trials. The clinical trials included participants who were obese or overweight and had at least one weight-related health condition. The most substantial weight reduction was observed in patients receiving the highest dose of orforglipron.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Become aBeta Tester

The drug functions by activating the GLP-1 receptor, akin to widely used injectable weight-loss drugs like Wegovy and Mounjaro, both also manufactured by Eli Lilly. Health tracking apps like Shotlee can help monitor progress with such medications. However, orforglipron is administered orally, potentially providing a more convenient option for patients.

Original source: News Directory 3

View original article →

#Eli Lilly#weight loss drug#orforglipron#obesity#clinical trials

GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction - News Update

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction

📱 Get the Shotlee App

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction - News Update

Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction

📱 Get the Shotlee App

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report